The novel bifunctional anti‐PD‐L1/TGF‐βRII targeting fusion protein, SHR‐1701, has also shown early promise in refractory solid tumours, including pancreatic cancer [122, 124]. This evidence concerns the gene CD274 and familial pancreatic carcinoma.